Medical Pharmacology Question Bank

Chapter 1: General Pharmacology — Module 2: Pharmacokinetics Principles
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions cover the pharmacokinetic framework — the principles that govern what the body does to a drug after administration. You will work through questions on first-pass metabolism and bioavailability, membrane crossing and the ionization barrier, volume of distribution, protein binding, half-life and steady state, hepatic Phase I and Phase II metabolism, renal elimination, and the clinical consequences of organ dysfunction on drug handling. Several questions involve calculation-based reasoning — bioavailability from plasma concentration data, dose adjustment for renal impairment, urine pH manipulation for overdose management. These are not abstract concepts: every dosing decision in clinical practice depends on them. Work through each question before reading the rationale.

1. A drug administered orally passes through the gut wall and enters the portal circulation before reaching systemic blood flow. A substantial fraction is metabolized by hepatic enzymes before it ever reaches the target organ. This phenomenon is called:

A) First-pass metabolism, which reduces the bioavailability of orally administered drugs that are extensively extracted by the liver before reaching the systemic circulation
B) Zero-order kinetics, in which a fixed amount of drug is eliminated per unit time regardless of plasma concentration
C) Enterohepatic recirculation, in which drug excreted in bile is reabsorbed from the intestine and returned to the portal circulation
D) Phase II metabolism, in which conjugation reactions convert lipophilic drugs to more water-soluble metabolites suitable for renal excretion
E) Saturation kinetics, in which metabolic enzymes become overwhelmed at high drug concentrations causing disproportionate plasma level increases

ANSWER: A

Rationale:

First-pass metabolism refers to the pre-systemic elimination of a drug that occurs after oral absorption but before it enters the systemic circulation. After absorption from the gastrointestinal tract, drug-laden portal blood flows directly to the liver, where hepatic enzymes — principally the cytochrome P450 system — may metabolize a substantial fraction of the absorbed dose before it reaches any target organ. The drug that survives this hepatic extraction then enters systemic circulation. The clinical consequence is that oral bioavailability can be dramatically lower than intravenous bioavailability for drugs with high hepatic extraction ratios. Classic examples include morphine, propranolol, lidocaine, and nitroglycerin — drugs that require either much higher oral doses than intravenous doses, or non-oral delivery routes entirely. Understanding first-pass metabolism is foundational to explaining why the same drug given by different routes requires different doses to achieve equivalent plasma concentrations.

2. Bioavailability (F) is the fraction of an administered dose that reaches the systemic circulation in active form. Which of the following correctly defines bioavailability and explains how it is measured?

A) Bioavailability equals the ratio of the drug's peak plasma concentration after oral dosing to the peak plasma concentration after intravenous dosing of the same dose — a ratio below 1.0 indicates incomplete absorption
B) Bioavailability equals the ratio of the volume of distribution after oral dosing to the volume of distribution after intravenous dosing — drugs with large volumes of distribution have low bioavailability because drug leaves the plasma rapidly
C) Bioavailability equals the ratio of the area under the plasma concentration-time curve (AUC) after the route in question to the AUC after intravenous dosing of the same dose — intravenous administration defines 100% bioavailability by convention
D) Bioavailability equals the fraction of a dose excreted unchanged in urine — drugs with high renal clearance have high bioavailability because they are not metabolized before reaching the kidney
E) Bioavailability equals one minus the hepatic extraction ratio — drugs that are not metabolized by the liver at all have zero bioavailability because they cannot be eliminated

ANSWER: C

Rationale:

Bioavailability is formally quantified by comparing the total drug exposure — measured as the area under the plasma concentration-time curve — after administration by a given route to the total drug exposure after intravenous administration of the same dose. AUC captures both the peak concentration and the duration of drug presence in plasma, making it a superior measure of systemic exposure compared to peak concentration alone. Intravenous administration delivers drug directly into the systemic circulation with no absorption step and no opportunity for first-pass extraction, so it defines 100% bioavailability by convention. If oral AUC is 40% of intravenous AUC, oral bioavailability is 0.40 — meaning the oral dose must be approximately 2.5 times the intravenous dose to achieve equivalent systemic exposure. Oral bioavailability is reduced by incomplete gut absorption, intestinal wall metabolism, and hepatic first-pass metabolism.

3. A drug molecule must cross biological membranes to move from the site of administration into the systemic circulation and from there into target tissues. The most common mechanism by which lipophilic, un-ionized small molecules traverse cell membranes is:

A) Active transport via ATP-dependent carrier proteins that move drug molecules against their concentration gradient — the primary mechanism for most small lipophilic drugs regardless of their physicochemical properties
B) Passive diffusion down the concentration gradient through the lipid bilayer — favored by high lipophilicity, low molecular weight, and un-ionized form of the drug at the pH of the membrane environment
C) Facilitated diffusion via specific membrane transporters that do not require energy but are saturable — the universal mechanism for all drugs regardless of their charge or lipid solubility
D) Pinocytosis, in which the cell membrane engulfs drug molecules in vesicles — the dominant mechanism for drugs with molecular weights above 200 daltons
E) Aqueous diffusion through membrane pores — the primary mechanism for lipophilic drugs because the lipid bilayer is impermeable to all molecules above 100 daltons

ANSWER: B

Rationale:

Passive diffusion through the lipid bilayer is the dominant membrane transport mechanism for the majority of clinically used drugs. The cell membrane consists of a phospholipid bilayer with a hydrophobic interior that presents a significant barrier to polar and ionized molecules while permitting lipophilic, un-ionized molecules to dissolve into and traverse the membrane along their concentration gradient. No energy expenditure and no carrier protein are required — movement is driven purely by the concentration difference across the membrane. Three physicochemical properties predict passive diffusion: lipophilicity (measured as logP), molecular size (smaller molecules diffuse more readily), and ionization state (un-ionized form diffuses; ionized form does not). This last property explains pH-dependent absorption — a weak acid is predominantly un-ionized in the acidic stomach environment and therefore absorbed there, while a weak base is better absorbed in the more alkaline small intestine.

4. The volume of distribution (Vd) is described as an apparent volume because it does not correspond to any real anatomical compartment. Which of the following best explains what a Vd of 700 L in a 70 kg adult tells a clinician about that drug?

A) The drug is confined almost entirely to the plasma compartment, because a volume far exceeding total body water confirms that the drug cannot cross vascular membranes
B) The drug distributes evenly throughout total body water (approximately 42 L) and the excess volume represents plasma protein binding, which mathematically inflates the apparent Vd beyond physiological fluid volumes
C) The drug is eliminated so rapidly by the kidneys that plasma concentrations fall before distribution can occur, producing an artificially large Vd calculation
D) The drug is extensively sequestered in peripheral tissues — bound to tissue proteins, dissolved in fat, or trapped intracellularly — leaving only a small fraction in plasma; such drugs have long half-lives, are not easily removed by dialysis, and require large loading doses
E) The drug undergoes saturation kinetics at therapeutic doses, which causes the Vd to expand proportionally with increasing dose as peripheral tissue binding sites become occupied

ANSWER: D

Rationale:

The volume of distribution is calculated as the dose divided by the plasma concentration at time zero after an intravenous bolus: Vd = Dose / C0. When Vd greatly exceeds total body water (approximately 42 L in a 70 kg adult), it means that the plasma concentration is very low relative to the total amount of drug in the body — which can only happen if most of the drug has left the plasma and sequestered in peripheral tissues. The drug is bound to tissue proteins, dissolved in fat depots, or trapped intracellularly, with only a small fraction remaining in the vascular compartment where it can be measured. This has three important clinical consequences: such drugs have long elimination half-lives (because little drug is available in plasma for hepatic or renal clearance); they are not effectively removed by hemodialysis (because the plasma drug reservoir that dialysis accesses represents only a tiny fraction of total body drug); and they require large loading doses to saturate peripheral compartments before therapeutic plasma concentrations are achieved. Digoxin (Vd approximately 500 L) and chloroquine (Vd approximately 200-800 L/kg) are classic examples.

5. Most drugs are eliminated from the body following first-order kinetics. Which of the following correctly describes first-order elimination and its most important clinical implication?

A) A fixed amount of drug is eliminated per unit time regardless of plasma concentration — this means that doubling the dose doubles the time required to eliminate the drug, making dose adjustments straightforward
B) The rate of elimination is proportional to the square of the plasma concentration — this produces a J-shaped plasma concentration-time curve and means that small dose increases cause disproportionately large rises in steady-state plasma levels
C) Elimination rate is independent of plasma concentration because metabolic enzymes are always saturated at therapeutic doses — this is why most drugs require loading doses to achieve rapid therapeutic levels
D) The rate of elimination increases linearly with plasma concentration up to a maximum rate (Vmax), after which the rate plateaus and remains constant — this is the mechanism underlying first-order kinetics for all drugs at therapeutic doses
E) The fraction of drug eliminated per unit time is constant regardless of plasma concentration — a constant percentage of the remaining drug is cleared each hour, producing an exponential decline in plasma concentration and a predictable half-life

ANSWER: E

Rationale:

First-order elimination means that a constant fraction of the drug present in the body is eliminated per unit time — not a constant amount, but a constant proportion. If 20% of the drug is eliminated per hour, then a plasma level of 100 mg/L falls to 80 mg/L in the first hour, then to 64 mg/L in the second hour, and so on. The rate of elimination in absolute terms slows as drug accumulates, but the fraction eliminated per hour remains constant. This produces an exponential decline in plasma concentration when plotted on a linear scale, and a straight line when plotted on a log scale. The most important clinical implication is that the half-life — the time required for plasma concentration to fall by 50% — is constant and independent of the starting concentration for a first-order drug. This predictability allows clinicians to calculate dosing intervals, time to steady state (approximately 4-5 half-lives), and time for drug washout after stopping therapy. The vast majority of drugs at therapeutic doses follow first-order kinetics.

6. Half-life (t½) is one of the most clinically useful pharmacokinetic parameters. Which of the following statements about half-life is correct?

A) Half-life determines only the time to reach steady state during repeated dosing — it has no relationship to the appropriate dosing interval or to the time required for drug washout after stopping therapy
B) For a drug following first-order kinetics, half-life is calculated as 0.693 × Vd / CL, where Vd is volume of distribution and CL is clearance — this means half-life increases when Vd increases or when CL decreases
C) Half-life is equivalent to the dosing interval — a drug with a half-life of 12 hours must always be dosed every 12 hours to maintain therapeutic plasma concentrations
D) Half-life is a primary pharmacokinetic parameter that is independent of both volume of distribution and clearance — it is determined solely by the rate of absorption from the site of administration
E) Drugs with longer half-lives reach steady state more rapidly than drugs with shorter half-lives, because the body retains more drug between doses and accumulation therefore occurs faster

ANSWER: B

Rationale:

Half-life is a derived pharmacokinetic parameter — it is not independently determined but is instead the mathematical consequence of two primary parameters: volume of distribution (Vd) and clearance (CL). The formula t½ = 0.693 × Vd / CL reflects this dependency directly. A drug with a large Vd has a long half-life because a large amount of drug is stored in peripheral tissues and must be mobilized back into plasma before it can be cleared — even if clearance itself is normal. Conversely, a drug with high clearance has a short half-life because what is in the plasma is rapidly eliminated. This relationship explains many clinical observations: renal failure prolongs the half-life of renally cleared drugs by reducing CL; hepatic failure prolongs the half-life of hepatically metabolized drugs for the same reason; severe hypoalbuminemia can alter Vd and thereby affect half-life even without any change in organ function. The 0.693 factor is the natural logarithm of 2, which arises from the mathematics of exponential decay.

7. Many drugs bind reversibly to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Which of the following correctly describes the clinical significance of plasma protein binding?

A) Only the unbound (free) fraction of drug is pharmacologically active, able to cross membranes, and available for metabolism and excretion — protein binding acts as a reservoir that buffers free drug concentrations and prolongs drug action
B) Protein-bound drug is more pharmacologically active than free drug because binding to albumin delivers the drug directly to its target receptor via albumin-receptor interactions in target tissues
C) Plasma protein binding increases the volume of distribution of highly bound drugs because bound drug cannot leave the plasma, concentrating drug in the vascular compartment and raising the calculated Vd
D) Protein binding is clinically irrelevant for most drugs because total plasma drug concentrations (bound plus free) are always measured by standard laboratory assays and these values directly predict pharmacological effect
E) Drugs that are highly protein-bound are always eliminated more rapidly than poorly bound drugs because protein binding facilitates renal filtration through the glomerular membrane

ANSWER: A

Rationale:

Plasma protein binding is a reversible interaction that creates two distinct drug populations in the bloodstream: bound drug and free (unbound) drug. Only the free fraction can cross biological membranes, interact with receptors, be filtered by the glomerulus, enter hepatocytes for metabolism, or produce pharmacological effects. Bound drug is pharmacologically inert and cannot be eliminated — it represents a circulating reservoir that maintains a gradient driving drug off the protein as free drug is consumed or cleared. This buffering effect means that protein binding extends drug action by slowing the net rate of elimination. When protein binding is reduced — by hypoalbuminemia, uremia, or drug displacement interactions — the free fraction rises and pharmacological effect intensifies even though total plasma concentration may appear unchanged. This is clinically significant for highly protein-bound drugs with narrow therapeutic indices such as warfarin, phenytoin, and valproic acid, where even small changes in free fraction can cause toxicity.

8. Hepatic drug metabolism is conventionally divided into Phase I and Phase II reactions. Which of the following correctly distinguishes these two phases?

A) Phase I reactions always produce pharmacologically inactive metabolites, while Phase II reactions always produce active metabolites — this is why prodrugs require Phase II metabolism to become therapeutically active
B) Phase I reactions occur in the renal tubule and convert lipophilic drugs to water-soluble glucuronide conjugates, while Phase II reactions occur in hepatocytes and introduce functional groups via oxidation, reduction, and hydrolysis
C) Phase I reactions introduce or unmask functional groups (via oxidation, reduction, or hydrolysis — primarily through the cytochrome P450 system) to increase reactivity; Phase II reactions conjugate these groups with endogenous molecules such as glucuronate, sulfate, or glutathione to increase water solubility and facilitate excretion
D) Phase I and Phase II reactions are functionally interchangeable — the designation refers only to the anatomical location within the hepatic lobule where metabolism occurs, not to the chemical nature of the reaction
E) Phase I reactions require the cytochrome P450 system and always activate drugs, while Phase II reactions require UDP-glucuronosyltransferases and always inactivate drugs — drugs that skip Phase I cannot undergo Phase II metabolism

ANSWER: C

Rationale:

Hepatic drug metabolism is organized into two sequential phases with distinct chemical roles. Phase I reactions introduce or expose a functional group — typically a hydroxyl, amino, thiol, or carboxyl group — through oxidation, reduction, or hydrolysis. The cytochrome P450 (CYP) enzyme superfamily, located in the smooth endoplasmic reticulum of hepatocytes, is responsible for the majority of Phase I oxidative reactions. Phase I metabolites are often more polar than the parent drug, but they may be pharmacologically active, inactive, or even more toxic than the original compound. Phase II reactions then conjugate these functional groups (or pre-existing groups on the original drug) with endogenous polar molecules — most commonly glucuronic acid (via UDP-glucuronosyltransferases), sulfate, glutathione, or acetyl or methyl groups. Conjugation greatly increases water solubility, typically renders the metabolite pharmacologically inactive, and prepares the molecule for biliary or renal excretion. Not all drugs require both phases — some are directly conjugated in Phase II without prior Phase I modification.

9. The cytochrome P450 (CYP) enzyme system is the dominant pathway for Phase I drug metabolism in the liver. Which of the following statements about CYP enzymes is correct?

A) All CYP enzymes are encoded by a single gene and differ only in their subcellular location — CYP enzymes in the smooth endoplasmic reticulum metabolize most drugs, while mitochondrial CYP enzymes handle endogenous steroids
B) CYP enzyme activity is fixed at birth by genetic factors alone and cannot be altered by drug exposure, diet, or disease — this is why CYP genetic testing reliably predicts drug metabolism for all patients
C) CYP enzymes metabolize drugs through a single universal reaction: hydroxylation of aromatic rings — other oxidative reactions attributed to CYP enzymes are actually performed by flavin monooxygenases
D) The CYP system consists of a superfamily of heme-containing enzymes with overlapping substrate specificities; specific isoforms including CYP3A4, CYP2D6, CYP2C9, and CYP1A2 account for the majority of hepatic drug oxidation, and their activity can be induced or inhibited by drugs, foods, and environmental exposures
E) CYP enzymes are expressed exclusively in the liver — intestinal, pulmonary, and renal CYP expression does not contribute meaningfully to systemic drug metabolism under any clinical circumstance

ANSWER: D

Rationale:

The cytochrome P450 system is a superfamily of heme-containing monooxygenases named for their characteristic spectrophotometric absorption at 450 nm when bound to carbon monoxide. Humans express more than 50 CYP isoforms, but a small subset — particularly CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 — accounts for the metabolism of the vast majority of clinically used drugs. CYP3A4 alone is responsible for approximately 50% of hepatic drug oxidation. These isoforms have overlapping but distinct substrate specificities and are subject to both induction and inhibition by other drugs, dietary constituents (notably grapefruit juice inhibiting CYP3A4), and environmental exposures. Induction — upregulation of CYP expression, classically by rifampin, carbamazepine, or St. John's wort — accelerates metabolism and reduces drug effect. Inhibition — competitive or mechanism-based blockade of the enzyme — slows metabolism and can cause dangerous drug accumulation. Understanding which CYP isoforms metabolize a given drug is essential to anticipating clinically significant drug interactions.

10. The kidneys eliminate drugs through three distinct processes. Which of the following correctly identifies all three and explains how they interact to determine net renal drug clearance?

A) Glomerular filtration, active tubular secretion, and passive tubular reabsorption — net renal clearance equals filtration plus secretion minus reabsorption; a highly lipophilic drug that is freely filtered and not secreted will nonetheless have low net renal clearance because it is almost completely reabsorbed in the tubule
B) Glomerular filtration, active tubular secretion, and glomerular reabsorption — net renal clearance equals filtration plus secretion minus glomerular reabsorption; tubular processes play no role in determining net renal clearance for most drugs
C) Passive filtration, facilitated secretion, and osmotic reabsorption — net renal clearance is determined entirely by urine flow rate, and increasing fluid intake is the primary clinical strategy for accelerating drug elimination in overdose
D) Glomerular filtration and tubular secretion only — tubular reabsorption is a negligible process that applies only to endogenous substances such as glucose and amino acids, not to exogenous drugs
E) Active filtration, passive secretion, and mandatory reabsorption — all filtered drugs are mandatorily reabsorbed unless active tubular secretion is also present, which is why only drugs with specific tubular secretion transporters can be renally eliminated

ANSWER: A

Rationale:

Renal drug elimination involves three distinct processes working in concert. Glomerular filtration is a passive, non-saturable process that filters free (unbound) drug from plasma at a rate governed by the glomerular filtration rate (GFR); protein-bound drug cannot be filtered because it is too large to pass through glomerular pores. Active tubular secretion uses energy-dependent carrier proteins in the proximal tubule — including organic anion transporters (OAT) and organic cation transporters (OCT) — to move drug from peritubular capillary blood into the tubular lumen; this process can handle both free and protein-bound drug, is saturable, and is subject to competitive inhibition. Passive tubular reabsorption occurs in the distal tubule and collecting duct, where lipophilic un-ionized drug diffuses back across the tubular epithelium from the concentrated urine back into the bloodstream. Net renal clearance is the algebraic sum: CLrenal = CLfiltration + CLsecretion — CLreabsorption. The consequence is that lipophilic drugs, even if freely filtered, are extensively reabsorbed and have low net renal clearance — which is why Phase I and II hepatic metabolism is necessary to convert them to more polar, less reabsorbable metabolites before they can be efficiently excreted in urine.

11. During repeated drug dosing, plasma concentrations accumulate until a steady state is reached. Which of the following correctly describes steady state and the factors that determine when it is achieved?

A) Steady state is reached when the total amount of drug in the body equals the volume of distribution — this occurs after a number of doses equal to the Vd divided by the dose administered per interval
B) Steady state is reached when the rate of drug input equals the rate of drug elimination — for drugs following first-order kinetics, this occurs after approximately 4 to 5 half-lives of continuous dosing at a fixed dose and interval, regardless of the dose size or dosing frequency
C) Steady state is reached after a fixed number of doses (always 10 doses) regardless of the drug's half-life — the dose size determines the plasma concentration at steady state, while the number of doses determines the time to reach it
D) Steady state is reached when plasma drug concentration no longer fluctuates between doses — for drugs with very short half-lives this never occurs because the drug is completely eliminated between each dose before the next dose can accumulate
E) Steady state is reached more rapidly with smaller doses because lower plasma concentrations are cleared more efficiently by first-order kinetics, so the time to accumulation is inversely proportional to dose size

ANSWER: B

Rationale:

Steady state is the condition in which the rate of drug input into the body equals the rate of drug elimination, so that the average plasma concentration remains constant over repeated dosing cycles even though concentrations still fluctuate between peak and trough within each dosing interval. For drugs following first-order kinetics, the time to reach steady state is determined exclusively by the half-life — approximately 4 to 5 half-lives of consistent dosing are required regardless of dose size or dosing frequency. A drug with a 6-hour half-life reaches steady state in about 24-30 hours; a drug with a 40-hour half-life (such as phenobarbital) requires 7-10 days. The dose size and dosing frequency determine the plasma concentration at steady state and the degree of peak-to-trough fluctuation, but they do not change the time to reach steady state. This principle has direct clinical consequences: if a patient is changed to a new maintenance dose, it takes 4-5 half-lives to reach the new steady state, meaning that dose adjustments cannot be assessed immediately for long-half-life drugs.

12. A patient with chronic kidney disease has a glomerular filtration rate (GFR) of 20 mL/min (normal: 90-120 mL/min). She is prescribed a drug that is 80% eliminated unchanged by the kidneys and has a half-life of 8 hours in patients with normal renal function. Which of the following best predicts the pharmacokinetic consequence of her renal impairment?

A) Her renal impairment will have no clinically significant effect on this drug's half-life because the liver will compensate by increasing Phase I metabolism to handle the fraction of drug that the kidneys can no longer clear
B) Her renal impairment will reduce the drug's volume of distribution, causing higher peak plasma concentrations after each dose but no change in the elimination half-life
C) Her renal impairment will substantially reduce the renal clearance of this drug, prolonging its half-life well beyond 8 hours and causing drug accumulation with standard dosing — dose reduction, dosing interval extension, or both will be required to prevent toxicity
D) Her renal impairment will increase the drug's oral bioavailability by reducing renal first-pass extraction, which partially compensates for reduced elimination and keeps steady-state concentrations within the therapeutic range without dose adjustment
E) Her renal impairment will cause the drug to shift from first-order to zero-order kinetics, producing unpredictable plasma concentrations that cannot be managed by standard dose adjustment formulas

ANSWER: C

Rationale:

When a drug is predominantly renally eliminated and renal function is significantly impaired, the clearance of that drug falls proportionally. Since half-life is directly dependent on clearance (t½ = 0.693 × Vd / CL), a reduction in CL produces a proportional increase in half-life. A drug with 80% renal elimination and a GFR reduced to approximately 20% of normal will have its renal clearance reduced to approximately 20% of normal; the overall drug clearance falls substantially, and the half-life extends accordingly — potentially to 3-4 times the normal value or more depending on the non-renal clearance contribution. Drug will accumulate at standard doses and intervals until toxicity supervenes. The clinical response is dose reduction, extension of the dosing interval, or both, guided by the degree of renal impairment. Many reference sources including drug labeling and renal dosing guides provide specific recommendations based on GFR or creatinine clearance. This is the fundamental pharmacokinetic rationale for renally adjusting drugs in patients with chronic kidney disease — the half-life governs accumulation risk.

13. A loading dose is sometimes used at the start of therapy to rapidly achieve therapeutic plasma concentrations. Which of the following correctly explains why a loading dose is necessary for some drugs and how it is calculated?

A) A loading dose is required for all drugs with short half-lives because they are eliminated so rapidly that the maintenance dose cannot sustain any plasma concentration — the loading dose creates a reservoir in peripheral tissues that the maintenance dose then replenishes
B) A loading dose is required when the desired therapeutic plasma concentration must be achieved immediately and cannot await the 4 to 5 half-lives required to reach steady state with maintenance dosing alone — it is calculated as the target plasma concentration multiplied by the volume of distribution, and it is particularly important for drugs with long half-lives
C) A loading dose equals one maintenance dose given at a shorter interval — the clinical convention is to give the first two doses simultaneously when immediate effect is needed, regardless of the drug's pharmacokinetic properties
D) A loading dose is calculated as the target concentration divided by the clearance, and it is primarily used for drugs with narrow therapeutic indices to prevent subtherapeutic plasma levels during the distribution phase
E) A loading dose is only used for intravenous drug administration — oral drugs cannot be given loading doses because first-pass metabolism eliminates the pharmacokinetic advantage of giving a larger initial dose

ANSWER: B

Rationale:

For drugs with long half-lives, the time required to reach therapeutic steady-state plasma concentrations with maintenance dosing alone can be clinically unacceptable. A drug with a 40-hour half-life requires 7-10 days to reach steady state — in acute illness, waiting that long for therapeutic drug levels may cause serious harm. The loading dose solves this problem by immediately filling the apparent volume of distribution to the target plasma concentration. The calculation follows directly from the definition of Vd: if Vd = Dose / C, then Loading Dose = Target Concentration × Vd. Once the loading dose has distributed and established the desired plasma concentration, maintenance dosing at the appropriate rate maintains that concentration at steady state by replacing what is cleared. Classic examples include digoxin, amiodarone, and phenytoin — all with long half-lives where immediate therapeutic levels are clinically necessary. The loading dose strategy is particularly important to understand because it distinguishes the pharmacokinetic goal of rapid attainment of therapeutic levels from the pharmacokinetic goal of maintaining them.

14. A clinician is managing a patient on phenytoin for epilepsy. The patient's seizures are well controlled at a total phenytoin level of 14 mg/L. The dose is increased by 50 mg/day to achieve better control. Instead of the expected modest rise in plasma concentration, the level jumps to 28 mg/L and the patient develops signs of toxicity. Which pharmacokinetic phenomenon explains this disproportionate response to a small dose increase?

A) Phenytoin has a very large volume of distribution, so small dose increases cause disproportionate rises in plasma concentration because there is no peripheral compartment available to absorb the additional drug
B) Phenytoin is a potent CYP enzyme inducer that paradoxically inhibits its own metabolism at higher doses through a negative feedback mechanism, causing sudden accumulation when doses exceed a threshold
C) Phenytoin undergoes enterohepatic recirculation that saturates at higher doses, causing the recycled drug to accumulate in plasma rather than being excreted in bile
D) Phenytoin metabolism follows Michaelis-Menten (saturation) kinetics — at lower concentrations the CYP2C9 enzyme system has ample spare capacity and behaves approximately as first-order, but at the concentrations produced by the dose increase, the enzymes become saturated and the drug shifts toward zero-order elimination, where a small dose increase causes a disproportionate rise in steady-state plasma concentration
E) Phenytoin has a very short half-life at therapeutic doses that suddenly lengthens at toxic doses due to competitive inhibition of CYP2C9 by phenytoin metabolites, which accumulate and block further parent drug metabolism

ANSWER: D

Rationale:

Phenytoin is the classic clinical example of a drug that exhibits Michaelis-Menten (saturation) kinetics within the therapeutic range. At low plasma concentrations the hepatic CYP2C9 and CYP2C19 enzymes responsible for phenytoin hydroxylation have substantial reserve capacity, and elimination approximates first-order behavior — a constant fraction of drug is cleared per unit time and plasma concentration rises predictably with dose. However, as concentrations approach the therapeutic range (10-20 mg/L), the metabolic enzymes begin to approach saturation. At this point, even a small dose increase pushes the system from the quasi-linear portion of the Michaelis-Menten curve into the near-saturated range, where elimination rate is nearly maximal and essentially constant (approaching zero-order). In zero-order kinetics, the rate of elimination is fixed regardless of concentration — so any additional drug input causes concentration to rise until a new, much higher steady state is reached. The clinical lesson is critical: phenytoin dose adjustments in the therapeutic range must be made in very small increments (typically 25-30 mg/day), and plasma levels must be monitored carefully after each adjustment because the relationship between dose and steady-state concentration is non-linear and unpredictable near saturation.

15. A clinician wants to alkalinize the urine of a patient who has ingested a large overdose of a weak acid drug (pKa 4.5) in order to accelerate its renal elimination. Which of the following correctly explains the pharmacokinetic rationale for this intervention?

A) Urine alkalinization increases the glomerular filtration rate, allowing the kidneys to filter more drug per minute and thereby accelerate elimination regardless of the drug's ionization state in tubular fluid
B) Urine alkalinization activates organic anion transporters in the proximal tubule, which actively secrete the drug from peritubular capillaries into the tubular lumen at a higher rate when urine pH is elevated
C) In alkaline urine, a weak acid drug is predominantly in its ionized form — ionized molecules are polar and membrane-impermeable, so they remain trapped in the tubular lumen rather than being reabsorbed back into the bloodstream, increasing net urinary excretion of the drug
D) Urine alkalinization converts the weak acid drug to its lipophilic un-ionized form in the tubular lumen, which is then reabsorbed more efficiently by the tubular epithelium, paradoxically increasing plasma drug levels rather than reducing them
E) Urine alkalinization denatures the weak acid drug by raising the pH above its pKa, permanently inactivating it and allowing the kidneys to excrete the denatured fragments more rapidly through aqueous pore diffusion

ANSWER: C

Rationale:

The pharmacokinetic rationale for urine alkalinization in weak acid overdose rests on the Henderson-Hasselbalch equation and its consequences for passive tubular reabsorption. A weak acid drug exists in equilibrium between its un-ionized form (HA) and its ionized form (A⁻), governed by the local pH relative to the drug's pKa. In alkaline urine (pH elevated by sodium bicarbonate infusion), the equilibrium shifts strongly toward the ionized form A⁻. Ionized molecules are polar, water-soluble, and cannot diffuse across the lipid bilayer of tubular epithelial cells — they are membrane-impermeable and therefore cannot be passively reabsorbed. The drug remains trapped in the tubular lumen, is carried forward with urine flow, and is excreted. This is called ion trapping. The same principle operates in reverse for weak bases in acidic urine — acidification promotes ionization of weak bases, trapping them in the tubular lumen. Ion trapping is clinically used for salicylate overdose (urine alkalinization with sodium bicarbonate) and for some amphetamine toxicity cases (historically managed with urine acidification, though this is now rarely practiced due to risks). The degree of benefit depends on the fraction of total drug clearance accounted for by renal elimination and the degree of pH change achievable.

BEFORE YOU MOVE ON

You have worked through 15 questions covering the pharmacokinetic framework that governs drug behavior in the body — oral bioavailability and first-pass extraction, membrane permeability and the Henderson-Hasselbalch principle, volume of distribution and its clinical implications, plasma protein binding, hepatic metabolism through Phase I and Phase II pathways, renal elimination and the three tubular processes, half-life and steady-state accumulation, and the dose adjustment strategies required in renal and hepatic disease. These pharmacokinetic principles form the mechanistic foundation for understanding drug interactions, toxicity, and individual variation in drug response. Tier 1 builds on this framework by placing you in clinical scenarios where pharmacokinetic reasoning drives patient-specific dosing decisions.